The Scientist - Home

WHAT FOLLOWS TAMOXIFEN? Warnings accompanied recent announcements from the University of Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project and the National Cancer Institute in Bethesda, Md., that tamoxifen achieved a 45 percent reduction in the incidence of breast cancer compared to women who took a placebo in the Breast Cancer Prevention Trial. The 25-year-old drug still carries the risk of serious side effects for women over 50, officials said. But the overall results were

Seven life scientists are among the 15 honorees for this year's National Academy of Sciences award ceremony set for today at the NAS's 135th annual meeting in Washington, D.C. The meeting also includes the induction of academy members elected last year (E.R. Silverman, The Scientist, 11[9]:1, April 28, 1997). The academy is presenting its highest honor, the Public Welfare Medal, to David A. Hamburg, president emeritus of the Carnegie Corp. of New York. Hamburg, 72, is being recognized "for his

PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new

ACADEMIC EROSION: Although neither males nor females approach NSF's goals for attracting students to science and engineering careers (represented by dotted line), women tend to flee the sciences faster than men--particularly after high school. First came the age of intrepid female pioneer researchers. Then came the epoch of "supermom" scientists. So where do women in science stand today? Many presenters at the Conference on Women, Science, and Engineering held last month at the New York Acade

New machines and approaches are offering neuroscientists unprecedented access to the working human brain By Douglas Steinberg Photo: Neil Michel/Axiom Sylvia WIRED FOR AN IMAGE: Research associate Valerie Clark gets her brain waves recorded by Ron Mangun, a psychology professor at the University of California, Davis. Mind-reading, that staple of science fiction, is inching closer to science fact, thanks to steady progress in the field of brain imaging. In the last few years, neuroimagers hav

SAFER CANCER GENE THERAPY A twist on a well-studied gene therapy may more safely melt tumors. In clinical trials, a herpes simplex gene encoding the enzyme thymidine kinase (TK) is delivered, via a retrovirus vector, to dividing brain cancer (glioma) cells. The infected cells produce TK, which kills them when the patient takes the anti-herpes drug ganciclovir. But viral vectors are risky--they can enter the nucleus during cell division and disrupt genes. Thomas Wagner, a distinguished professor

Swiss anthropologist Jeremy Narby counts himself among the relatively thin ranks of scientists willing to publicly announce their conviction that nature is "minded," that an intelligence lies behind the development of life. Such a position is heresy to the prevailing scientific view of naturalism, which holds that nature is self-sufficient and the result of undirected processes. These two differing viewpoints usually are framed in the context of a debate between theology and science--creationis

'BODY-COUNT BUDGETING'? Rep. Ernest Istook (R-Okla.) is concerned that diseases that cost taxpayers the most money may not be getting a proportionate amount of NIH funds. For the third year in a row, the National Institutes of Health came under fire this month for slighting some diseases and favoring more politically correct ills when it parcels out its research-funding billions. "What this whole thing boils down to," NIH director Harold Varmus recently told a special Institute of Medicine (I

Consumers distrust some of the field's developments and put too much hope in other, well-publicized studies. CALLING ALL SCIENTISTS: The best source of information on biotech, says Carl Feldbaum of the Biotechnology Industry Organization, is the scientist, who can really help educate the press and the public. The public's fears when modern biotechnology began two decades ago have both diminished and evolved. Surveys indicate that today, many people accept that biotechnology will increasingly

Mouse has a kinky-waltzer. Drosophila has a bride of sevenless. Yeast has a Wee-1. Gene and protein names often are based on the flamboyant, the descriptive, and the intentionally obscure. For many researchers, naming their discovery may be a rare opportunity to imbue their science with creativity. (See list on page 6 for origins of these names.) NOMEN-CLUTTER: Multiple names for genes and gene products causes confusion, says University of Alberta's Lawrence Puente. But creativity plus

Contents Moral Might Self-Validation More Alzheimer's Progress Broader Role For Mobile DNA Preferential Hearing Special Delivery Perfect Pitch Genes Imaging Dsylexia Date: March 30, 1998 A GUIDE TO ETHICS: Eric Meslin took over leadership of the National Bioethics Advisory Commission last month. MORAL MIGHT Eric M. Meslin, 36, has taken over leadership of the National Bioethics Advisory Commission (NBAC) in Rockville, Md. Harold T. Shapiro, NBAC's chairman and president of Princeton Univers

Although newly degreed life scientists may be ready for employment in an academic setting, they often come to the business world unprepared for the fast-paced, team-based, results-oriented environment of today's life science industry, a variety of observers from industry and academia assert. Some university and business leaders are helping to rectify such problems by teaming up to create educational programs focused on the business side of science. OFFERING AN ALTERNATIVE: Henry Riggs, preside